

INSTRUCTIONS						
Complete this reporting for clearly attributed to other ca	m for AEFIs which h	ave a temp	oral association with a	vaccine and which	cannot be	Reporting Tips
Public health staff: Enter in	•		•		unis ionn.	Refer to the User
Community vaccine provide	ers: Submit the com	pleted form	to public health. Com	plete all pertinent fi		Guide for Completion and
Section G. See the AEFI rep	- · <u> </u>			-	-	Submission of AEFI
For additional information of for subsequent immunization						Reports for full instructions.
Immunization.						
REPORTER INFORMATION						
Health Authority: FHA	IHA 🗆	NHA 🗆	VCH 🗆 VIHA	D PHSA D	FNHA	
Setting: Physician office	Public health	ospital 🛛	Pharmacy 🛛 Health a	authority workplace he	ealth	
□ Other, <i>specify:</i>						
Name:		Phone Nur	mber: ()	-	ext.	Reporter is the health care provider who
Last Fi	irst	Fax Numb	or ()			received and reported the AEFI information to
Address:		Fax Numb	Branch Office:	-		the public health unit.
	1		(if applicable)			
Province/Territory:	Postal code:		Date reported:	YYYY/MM/DD		
Signature:						
Signature: Implement of the provided and the						
A. SOURCE OF INFORMAT				0///1		
		ed to public h	health unit hy"			
Only complete Section A if "Other" selected for "Reported to public health unit by" Name: Phone Number: ()						1
Last First () - ext.					Source of information can be the same as	
Email: Relationship to client:						reporter, the client, or a secondary source such as a parent/guardian.
Address:						
Unit #	Street #		treet Name rovince:	C	ity	
B. CLIENT INFORMATION						
Name:	Fir	st		Middle		
Date of Birth:	Gender:	🗆 Mal	le 🛛 Female	Transgender	Unknown	
YYYY/MM/DD Health Card Number:						Adverse event ID
Health Card Number: Alternate Name(s):					and PARIS ID are system generated	
Phone Number (home/work/mobile): () - ext. IDs, not reportable to local public health.						
Address: Unit # Street # Street Name City						Enter IMPACT Local
Postal Code:	Province:		Country of Residence (in	f not Canada):		Inventory Number if the report was received from
ADVERSE EVENT ID: IMPACT LIN: PARIS ID:						
PATIENT'S PHYSICIAN (OR PRIMARY	CARE PROVIDER)					leave it blank.
Name: Phone Number () - Ext.]
Last First						-
Address:						



C. IMMUNIZ	ATION DATA								
Date vaccine administered^ YYYY/MM/DD	Immunizing agent	Trade name	Manufacturer	Lot number	Dose #	Dosage/ unit	Route	Site	
									^Date of vaccine
									administered should be the same for all
									vaccines associated with a single AEFI report.
Health Care Pro	vider who adminis	stered the vaccir	ie:	Phone	:				
Address:									
Un	it # Street #	Street	Name		City				
D. INFORM	ATION AT TIME	OF IMMUNIZ	ATION AND AE	FI ONSET					
	l low a previous d ot applicable (no p	-		zing agents list					
□ No □ N Comments:	or applicable (no p	nor doses)			provide dela	ans Delow.)			
comments.									
Did this AEFI f	ollow an incorred	t immunization	?						
🗆 No 🗖 Unki	nown 🛛 Yes (If y	/es , choose all t	hat apply and prov	/ide details below	N.):				
	tside the recomme	ended age limits		ired Dose		nat recomme	nded for ag	e	
Wrong vaccine given Incorrect route Other, specify									
Medical history (up to time of AEFI onset)? Check all that apply and provide details below.									
Concomitant			n medical conditio			illness/injur	y		
No known m	edical conditions(s) 🗌 Unkno	own at time of repo	ort					
Comments:									
asterisk (*)	AILS: Complete should be diagno	sed by a physici	an. If not, provide	sufficient inform	all signs/syn nation to sup	mptoms that port the sele	apply. Item ected item(s	(s) with). Use	
	for additional infor ion at or near inj	-	clinical details an	d test results.					
	-		<i>.</i>		st .	, ·			
Onset:			iys from immuniza			-			
Duration:	_Min. <i>or</i> +		iys from 1 st sympto	-				resolved	Select a local reaction before
Infected abs	_	Sterile abscess*		Cellulitis*	□ Nodule	🗆 Ra	ash		selecting corresponding
	ess or swelling ex	•	, –	Adenopathy/Lyr	mphadenitis	*			descriptors.
Pain or redn	ess or swelling pe	rsisting for 10 da	lys or more	Other, specify:					For tips on where to report rash see
									Section J.
Local reaction of	letails continue on	next page.							



E. AEFI DETAILS continued						
E1. Local reaction at or near injection site continued						
If an injection site reaction is reported above, check all signs/symptoms that apply and provide details below:						
Swelling Pain Tenderness Erythema Warmth Induration						
Largest diameter of vaccination site reaction (cm): Site(s) of reaction (e.g., LA, RA):	Only select local					
Palpable fluctuance Fluid collection shown by imaging technique (e.g., MRI, CT, ultrasound)	Only select local signs/symptoms if one or more local					
□ Spontaneous/surgical □ Microbial results, <i>specify</i> □ Lymphangitic streaking □ Regional lymphadenopathy	reaction is reported.					
Comments:	Specify Microbial results in comment					
	box.					
E2. Anaphylaxis and other allergic events						
Onset:Min. orHrs. orDays from immunization to onset of 1 st symptom/sign						
Duration:Min. orHrs. or Days from 1 st symptom/sign to resolution of all symptoms/signsUnresolved						
□ Anaphylaxis □ Oculo-Respiratory Syndrome (ORS) □ Other allergic events						
For the event indicated above, select all symptoms/signs that apply and provide details in comments below.						
Skin/mucosal: Generalized: At injection site Non-injection site Urticaria Erythema						
□ Pruritus □ Prickly sensation □ Rash						
Localized: At injection site Non-injection site Urticaria Erythema	Choose allergic signs/symptoms only					
Pruritus Prickly sensation Rash	if one allergic event (anaphylaxis, ORS,					
Eye(s): Red bilateral Red unilateral Itchy	or Other allergic events) is being					
Angioedema:	reported.					
Eyelids Face Limbs Other, <i>specify:</i>	If a client only					
Cardiovascular: ☐ Measured hypotension ☐↓ central pulse volume ☐ Capillary refill time >3 sec	reports GI symptoms that are not allergic					
□ Tachycardia □↓ or loss of consciousness	in nature, report in the appropriate event in the "Other					
Respiratory:	event" section.					
 □ Dry cough □ Tachypnea □ Wheezing □ Increased use of accessory muscles □ Grunting □ Cyanosis □ Sore throat □ Indrawing/retractions 	For tips on where to report rash see					
□ Difficulty swallowing □ Chest tightness □ Difficulty breathing	Section J.					
Gastrointestinal:						
Laboratory: Mast cell tryptase elevation > upper normal limit						
Comments:						
Comments.						



Adverse Event Following Immunization (AEFI)

Case Report Form

E. AEFI DE	TAILS continue	d						
E3. Neurolog	ic event							
Onset:	Min. <i>or</i>	Hrs. or	Days from imm	unization to or	nset of 1 st sym	ptom/sign		
Duration:	Min. or	Hrs. or	_ Days from 1 st s	ymptom/sign t	o resolution of	all symptoms/si	gns 🛛 Unresolved	
□ Seizure(s)	(Check all that	apply):						
Febri	le 🛛 Afebrile	Unknown	type					tem (a) with actarial
□ Foca	l							Item(s) with asterisk (*) should be
<i>or</i> □ Gene	eralized, specify:	Tonic	🗆 Clonic 🛛 🗆 1	onic-clonic	□ Atonic	Myoclonic	□ Absence	diagnosed by a physician.
	essed by health c			□ No		•		Select the
	en loss of consci	•	□ Yes					appropriate
_	ous history of sei		☐ Febrile	☐ Afebrile				neurological event, before choosing
	sia/ Paraesthesi		all that apply):			, type		corresponding descriptors.
	ralized or							
Numl			rning 🛛 Form	nication 🗆 C	Other, specify:			Report "Myelitis/Transverse
Meningitis	s* 🛛 Enc	ephalopathy/E	Encephalitis*	🛛 Guillain-	Barre Syndro	me (GBS)*	Bell's Palsy*	myelitis, ADEM or SSPE" as "Other
Other para	alysis* 🛛 Of	her neurologi	cal diagnosis*, s	pecify:				neurological
For any neur	ological event ii	ndicated abov	e, check all that a	apply and pro	vide details ir	n comments be	low.	diagnosis, specify".
Depres	sed/altered level	of consciousne	ss/Lethargy/ Pers	onality change	lasting ≥24 hi	rs		Report Vaccine- associated Paralytic
Focal c	or multifocal neuro	· ·	□ Fever (≥38°C	, _	abnormality		EG abnormality	Poliomyelitis as
🗆 EMG a	bnormality [] Neuroimagin	g abnormality	🗆 Brain	/spinal cord hi	stopathologic ab	normality	"Other paralysis".
Comments:								
E4 Other det	fined events of i	ntorost						
Onset:	Min. or		Days from immu	nization to on	act of 1 st auma	tom/sign		
Duration:			Days from 1 st sy			-	ns 🛛 Unresolved	
-	Min. or -Hyporesponsiv	Hrs. or e Enisode* (a)		mptom/sign to	resolution of a	all symptoms/sig		-
		or/cyanosis	Reduced re	esponsiveness	/unresponsive	ness		
•	_	,	ed crying for ≥3 h	•				
🗆 Rash: (Ref	er to Immunization I	Manual, Part 5 foi	reporting criteria. F	or rash at injectio	on site or rash in	allergic reaction, u	se sections above.)	
🗆 Genera	lized 🛛 Loca	alized at non-inj	ection site					
🗆 Intussusc	eption*							
Hematoch	ezia*							
☐ Arthritis*:								Item(s) with asterisk
☐ Joint re		t warm to touch		0	imatory chang	es in synovial flu	lid	(*) should be
□ Parolitis*	(Faloliu gialiu Sw		and/or tendernes	5)				diagnosed by a physician.
	vtopenia*:							
	count <150×10 ⁹ /	L Detec	hial rash 🛛 🗆 C	other clinical ev	vidence of blee	eding		
☐ Fever ≥38°	C (Report only i	f fever occurs ii	n conjunction with	reportable eve	ent. For a neur	ological event us	se section above.)	
🗆 Syncope v	with injury							
	vitiri irijury							
Severe vo	miting							
Severe dia	miting arrhea							
Severe dia	miting arrhea	ed event(s) no	ot listed above (S	pecify and provid	de details in com	nments below)		
Severe dia	miting arrhea	ed event(s) no	ot listed above (S	pecify and provid	de details in com	nments below)		
Severe dia Other seri	miting arrhea	ed event(s) no	ot listed above (S	pecify and provid	de details in corr	nments below)		
Severe dia Other seri	miting arrhea	ed event(s) no	ot listed above (S	pecify and provid	de details in com	nments below)		



F. IMPACT OF AEFI, OUTCOME,	AND LEVEL C	OF CARE OF	BTAINED		
Highest impact of AEFI (Choose one of	the following):	Outcome a	t time of report (Choose o	ne of the following):	
Did not interfere with daily activities	s Dermanent disability/incapacity Fully recovered			Fully recovered	
Interfered but did not prevent daily	activities	□ Not y	yet recovered	Unknown	
Prevented daily activities		Deat	h; specify date:		
			YYYY/MM/L	DD	-
Highest level of care obtained (Choose			for a large lite and for a large l		Report assessment
Emergency visit Non-urgent			from a health professional		in an emergency room setting without
Admitted to Hospital (days)	OR 🗌 Resu	ulted in prolon	gation of existing hospitalization	ation (by days)	formal admission to
Hospital name:					hospital as "Emergency Visit".
Hospital admission date:		Hospital dis	charge date:		
	MM / DD		YYYY/MM/	DD	-
Treatment received: No Unknow	/n ∐ Yes				
Provide details of treatment, including sel	f- treatment:				
G. PUBLIC HEALTH RECOMMEN	DATIONS (Pro	ovide commen	nts. Use section H if extra sp	ace is required.) FOR PUBLIC F	IEALTH USE ONLY
□ No change to immunization schedule		Expert refe	erral, specify		
Determine protective antibody level, sp	pecify	Controlled	setting for next immunization	on, specify	
□ No further immunizations, specify		Active follo	ow up for AEFI recurrence a	fter next vaccine, specify	
□ Other, specify		No recommendaria	mendations		
Comments:					For public health
oomments.					use only.
					Provide name of
					MOH or designate
					making the recommendation.
Name:	Professional s	tatus: □MOH	/MHO DMD DRN DO	ther, specify:	
Phone: () -	Date		Signature:		1
	YYYY/MM/	DD			
Send a copy to: DCCDC Clier	nt's Physician	Other:			
H. SUPPLEMENTARY INFORMAT	ION				
Please indicate the section letter who	en providing deta	ails.			
Provide details of any investigation of selected item(s). Append information	or treatment for the	he recorded A	EFI. Provide sufficient infor	mation to support the	
Section Comments					



I. ADVERSE EVENTS FOLLOWING IMMUNIZATION – TEMPORAL CRITERIA

The length of time between vaccine administration and onset of symptoms is an important consideration in causality assessment. Temporal criteria guidelines in this table are generally agreed upon approximate timelines.

Reaction		Temporal Criteria			
Туре	Adverse Event Following Immunization	Inactivated Vaccines	Live Attenuated Vaccines		
at	Infected Abscess	0-7	days		
Local Reactions Injection Site	Sterile Abscess	0-7	days		
React	Cellulitis	0-7	days		
Injec	Nodule	0-7	days		
ΓC	Pain or Redness or Swelling	0-48 hours			
	Adenopathy/Lymphadenopathy	0-7 days	MMR: 5 - 30 days Varicella: 5 - 42 days		
	Fever	Timing in conjunction with ot	her reportable adverse events		
tions	Hypotonic-Hyporesponsive Episode (HHE)	0-48	hours		
Reac	Parotitis	Not applicable	MMR: 5-30 days		
amic	Orchitis	Not applicable	MMR: 5-30 days		
Systemic Reactions	Rash	0-7 days	MMR: 0 - 30 days Varicella: 0 - 42 days		
	Screaming/Persistent crying	0-72 hours			
	Severe Vomiting/Diarrhea	0-72 hours	Rotavirus: 0-7 days		
Allergic Reactions	Anaphylaxis	0-24	hours		
	Oculo-respiratory Syndrome (ORS)	0-24	hours		
ReA	Other Allergic Reactions	0-48	hours		
	Anaesthesia/Paraethesia	0-15 days	MMR: 0 - 30 days Varicella: 0 - 42 days		
	Bell's Palsy	0-3 months			
ents	Convulsion/Seizure	0-72 hours	MMR: 5 - 30 days Varicella: 5 - 42 days		
Neurological Events	Encephalopathy or Encephalitis or Acute Disseminated Encephalomyelitis (ADEM)	0-42 days	MMR: 5 - 30 days Varicella: 5 - 42 days		
ologi	Guillain-Barré syndrome (GBS)	0-8 weeks			
Neur	Meningitis	0-15 days	MMR: 5 - 30 days Varicella: 5 - 42 days		
	Subacute sclerosing panencephalitis (SSPE)	Not applicable	Up to 10 years following a measles- containing vaccine		
	Paralysis	0-15 days	OPV: 5 - 30 days Varicella: 5-42 days		
	Arthritis	0-30 days	MMR: 5 - 30 days Varicella: 0 - 42 days		
Other Events of Interest	Intussusception or Haematochezia	Not applicable	Rotavirus: 0-42 days		
Ever teres	Syncope with injury	0-30 minutes			
Dther In	Thrombocytopenia	0-30 days			
0	Other severe or unusual	A temporal association to immunization and for which there is no other known cause and not covered under the other categories			



J. Rash reporting tips

Localized rash at the injection site: Local reaction at or near injection site > Rash > Select details that apply > Specify any additional details in local comments.

Localized allergic rash: Anaphylaxis and other allergic events > Skin/mucosal > Localized > Select "At injection site" or "Non-injection site" > Select "Rash" > Specify details in allergic comments.

Generalized allergic rash: Anaphylaxis and other allergic events > Skin/mucosal > Generalized > Select "At injection site" and/or "Non-injection site" > Select "Rash" > Specify details in allergic comments.

Generalized rash: Other defined events of interest > Rash > Generalized > Specify details in other comments.

Localized rash at non-injection site: Other defined events of interest > Rash > Localized at non-injection site > Specify details in other comments.

NOTE: Additional relevant training materials and data standards are available on the Panorama Solution Partner Portal (<u>https://panoramacst.gov.bc.ca</u>) (login required).